Thursday, April 10, 2025 4:13:07 PM
Lets apply Implex total acquisition price to Sintx based on Ortho + Dental only (markets Implex could sell products into) based on current market value despite those markets being significantly larger than back in 2003. We will also not take into account the fact Si3N4 potential penetration within ortho far exceeds that of Implex's Hydrocel. Just simple apples to apples.
Ortho + Dental markets are now valued around $69bn. I proportionally adjust value for each market based on those market sizes compared to ortho+dental market. This is not how valuations are done, its only meant to be illustrative to help visualize Sintx IP true value.
Ortho + Dental = 232m
PPE 232*1.16 = 269m
Catheter 232*.8 = 185.6m
Wound Care 232 * .32 = 74.24m
Biosensors 232 * .42 = 97.44m
Armor Materials Market 232 * .196 = 45.47m
Cancer (Microsphere) 232 *.07 = 16.24m
Total Estimated value for Sintx IP for the above markets : $920m valuation
Below I total several market valuation for several potential markets that Sintx could sell product into including markets in the above list. Based on 330bn total market size multiplied by only 5% average penetration rate across all those markets and a 5% licensing fee.
Thats revenue of : $825m a year.
Based on that very conservative projection, that revenue level justifies a market valuation of multi-billion dollars far exceeding the valuation i put together above. That said, it would take years and tens of millions possibly over hundred of million in total for Sintx to bring products to above markets with its partners. Still as the above list does not encompass every market Sintx could sell into with its proprietary materials.
========================================
Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)
Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn
Cancer Treatment (microspheres) = $5-$15bn
Total = $330bn-340bn
Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
Ortho + Dental markets are now valued around $69bn. I proportionally adjust value for each market based on those market sizes compared to ortho+dental market. This is not how valuations are done, its only meant to be illustrative to help visualize Sintx IP true value.
Ortho + Dental = 232m
PPE 232*1.16 = 269m
Catheter 232*.8 = 185.6m
Wound Care 232 * .32 = 74.24m
Biosensors 232 * .42 = 97.44m
Armor Materials Market 232 * .196 = 45.47m
Cancer (Microsphere) 232 *.07 = 16.24m
Total Estimated value for Sintx IP for the above markets : $920m valuation
Below I total several market valuation for several potential markets that Sintx could sell product into including markets in the above list. Based on 330bn total market size multiplied by only 5% average penetration rate across all those markets and a 5% licensing fee.
Thats revenue of : $825m a year.
Based on that very conservative projection, that revenue level justifies a market valuation of multi-billion dollars far exceeding the valuation i put together above. That said, it would take years and tens of millions possibly over hundred of million in total for Sintx to bring products to above markets with its partners. Still as the above list does not encompass every market Sintx could sell into with its proprietary materials.
========================================
Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)
Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn
Cancer Treatment (microspheres) = $5-$15bn
Total = $330bn-340bn
Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
https://investorshub.advfn.com/Bostons-research-43724
Could it be that there is a strategy to distract people away from looking at basic data?
Is it an exercise to create forum verbiage to drown out any serious discussion of evidence?
Recent SINT News
- SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution • GlobeNewswire Inc. • 03/23/2026 01:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 09:00:53 PM
- SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 01:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 01:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:00:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:35:38 PM
- SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms • GlobeNewswire Inc. • 02/18/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:45:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:44:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:43:48 AM
- SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 • GlobeNewswire Inc. • 01/29/2026 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/12/2025 05:15:20 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/09/2025 10:01:07 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 01:00:05 PM
- SINTX Technologies to Participate in Sidoti & Company Investor Conference • GlobeNewswire Inc. • 12/08/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 01:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:35:26 PM
- SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants • GlobeNewswire Inc. • 12/01/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 01:05:43 PM
- SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies • GlobeNewswire Inc. • 11/13/2025 01:00:00 PM
